Drawing for CELTYMAX

USPTO serial 78520036

CELTYMAX

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
—
Law office
NEW APPLICATION PROCESSING

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CELTYMAX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

MAURY M TEPPER III WOMBLE CARLYLE SANDRIDGE & RICE PLLCPO BOX 831RALEIGH, NC 27602-0831UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of disorders of the nervrous system, the immune system, the cardiovascular system, the respiratory system, the cardiovascular system, the respiratory system, the musculoskeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in hematology, in oncology, in transplantation, in ophthalmology, for use in the gastroenterological area and the prevention and treatment of ocular disorders or diseases; anti-infectives, pharmaceutical preparations treating bacterial-based disease, antivirals, antibiotics, and antifungalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 22, 2005MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Feb 21, 2005ABN1ABANDONMENT - EXPRESS MAILED—
Feb 21, 2005EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Nov 30, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance